You just read:

U.S. FDA Approves ThromboGenics' JETREA® (Ocriplasmin) for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)

News provided by

ThromboGenics NV

18 Oct, 2012, 06:35 BST